Biologically relevant integration of transcriptomics profiles from cancer cell lines, patient-derived xenografts, and clinical tumors using deep learning
Science Advances · 17.01.2025 · 11 (3)
DOI: 10.1126/sciadv.adn5596 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 17.01.2025. Verfasst von Slavica Dimitrieva und 7 weiteren Autor:innen. Beteiligte Einrichtung: Disease Area Oncology, Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland. Hauptthemen laut MEDLINE: Deep Learning, Transcriptome, Neoplasms, Gene Expression Profiling. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Cell lines and patient-derived xenografts are essential to cancer research; however, the results derived from such models often lack clinical translatability, as they do not fully recapitulate the complex cancer biology. Identifying preclinical models that sufficiently resemble the biological characteristics of clinical tumors across different cancers is critically important. Here, we developed MOBER, Multi-Origin Batch Effect Remover method, to simultaneously extract biologically meaningful embeddings while removing confounder information. Applying MOBER on 932 cancer cell lines, 434 patient-derived tumor xenografts, and 11,159 clinical tumors, we identified preclinical models with greatest transcriptional fidelity to clinical tumors and models that are transcriptionally unrepresentative of their respective clinical tumors. MOBER allows for transformation of transcriptional profiles of preclinical models to resemble the ones of clinical tumors and, therefore, can be used to improve the clinical translation of insights gained from preclinical models. MOBER is a versatile batch effect removal method applicable to diverse transcriptomic datasets, enabling integration of multiple datasets simultaneously.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Disease Area Oncology, Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland.
- Disease Area Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
ORCID-Profile: Slavica Dimitrieva, Rens Janssens, Gang Li, Artur Szalata, Chintan Parmar
Zitieren
APA
Dimitrieva, S., Janssens, R., Li, G., Szalata, A., Gopalakrishnan, R., Parmar, C., Kauffmann, A., & Durand, E. Y. (2025). Biologically relevant integration of transcriptomics profiles from cancer cell lines, patient-derived xenografts, and clinical tumors using deep learning. Science Advances, 11(3). https://doi.org/10.1126/sciadv.adn5596
Vancouver
Dimitrieva S, Janssens R, Li G, Szalata A, Gopalakrishnan R, Parmar C, et al. Biologically relevant integration of transcriptomics profiles from cancer cell lines, patient-derived xenografts, and clinical tumors using deep learning. Science Advances. 2025;11(3). doi:10.1126/sciadv.adn5596
BibTeX
@article{Dimitrieva2025,
author = {Dimitrieva, Slavica and Janssens, Rens and Li, Gang and Szalata, Artur and Gopalakrishnan, Rajaraman and Parmar, Chintan and Kauffmann, Audrey and Durand, Eric Y},
title = {Biologically relevant integration of transcriptomics profiles from cancer cell lines, patient-derived xenografts, and clinical tumors using deep learning},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {3},
doi = {10.1126/sciadv.adn5596}
}
EUVIMED